Amicus Therapeutics Files 10-K, Confirms BioMarin Merger Progress with HSR Clearance and Strong 2025 Financials
FOLD has more than doubled off its 52-week low of $5.51.
Summary
Amicus Therapeutics' 10-K confirms the BioMarin acquisition is progressing with HSR clearance, alongside reporting strong 2025 financial results and key pipeline and patent updates.
Key Events · M&A and Partnerships · FOLD
-
BioMarin Acquisition Confirmed
Reaffirms the definitive merger agreement with BioMarin Pharmaceutical Inc. for $14.50 per share in cash, with the transaction expected to close in Q2 2026. This follows the PREM14A filing on January 21, 2026, and DEFM14A on February 2, 2026.
-
HSR Act Waiting Period Terminated
The FTC granted early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on February 11, 2026, satisfying a key regulatory condition for the merger's completion.
-
Strong 2025 Financial Performance
Reported audited full-year 2025 net product sales of $634.2 million, a 17% increase year-over-year, and a reduced net loss of $27.1 million, with positive net cash from operations of $33.1 million. This provides final details to the preliminary results announced in the 8-K on January 26, 2026.
-
Dimerix License Agreement for Phase 3 Candidate
Secured exclusive U.S. commercialization rights for Dimerix's Phase 3 FSGS drug candidate, DMX-200, with an upfront payment of $30 million, expanding the company's pipeline.
Analysis · FOLD · Life Sciences
This Annual Report on Form 10-K provides the definitive audited financial results for 2025, confirming strong revenue growth and a significant reduction in net loss. Crucially, it reiterates the pending acquisition by BioMarin Pharmaceutical Inc. for $14.50 per share and discloses the recent early termination of the HSR Act waiting period, a key regulatory milestone for the merger. The filing also details the Dimerix license agreement for a Phase 3 drug candidate and the settlement of patent litigation for Galafold, reinforcing the company's underlying business strength ahead of the acquisition.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FOLD was trading at $14.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.